Summary Parathyroid hormone-related protein (PTHrP) is the main cause of humoral hypercalcaemia of malignancy (HHM). We recently established a new human breast cancer cell line, designated KPL-3C, from the malignant effusion of a breast cancer patient with HHM. Morphological, cytogenetic and immunohistochemical analyses indicated that the cell line is derived from human breast cancer. The KPL-3C cells stably secrete immunoreactive PTHrP measured by a two-site immunoradiometric assay, possess both oestrogen and progesterone receptors and are tumorigenic in female nude mice. The addition of phorbol-12-myristate-13-acetate to the medium significantly increased PTHrP secretion from the cells. In contrast, hydrocortisone, medroxyprogesterone acetate and 22-oxacalcitriol decreased PTHrP secretion in a dose-dependent manner. Unexpectedly, a number of microcalcifications were observed in the transplanted tumours. Radiographical examination indicated that the microcalcifications in the tumours are very similar to those commonly observed in human breast cancer. These findings suggest that this KPL-3C cell line may be useful for studying the regulatory mechanisms of PTHrP secretion and the mechanisms that lead to the deposition of microcalcifications in breast cancer.
Parathyroid hormone-related protein (PTHrP) is a recently discovered protein sharing strong homology with parathyroid hormone in the N-terminal amino acid sequence as well as biological activity (Suva et al., 1987; Mangin et al., 1988) . This protein was originally isolated from human malignant tumours associated with humoral hypercalcaemia. A number of clinical studies indicate that PTHrP is the main cause of HHM (Burtis et al., 1990; Grill et al., 1991; Ratcliffe et al., 1992) . In other words, tumour-derived PTHrP acts as a circulating hormone like parathyroid hormone and induces hypercalcaemia. Recently, a series of studies has indicated that PTHrP is commonly expressed in breast cancer and that a higher expression of PTHrP may induce bone metastasis (Southby et al., 1990; Powell et al., 1991; Bundred et al., 1992; Vargus et al., 1992; Bouizar et al., 1993; Kohno et al., 1994a; Kohno et al., 1994b) . It is conceivable that the PTHrP secreted by breast cancer cells, which exist in bone marrow, may act as a paracrine effector on osteoclasts, resulting in osteolytic involvement. These findings suggest that the PTHrP secreted by malignant tumours may act as a hormone or paracrine effector in different pathological situations.
Microcalcifications are commonly observed in breast cancer tissues (Snyder and Rosen, 1971) . However, the mechanisms that lead to their deposition in the tissues are still poorly understood. Recently, the expression of bone sialoprotein, a bone matrix protein, in breast cancer cells was demonstrated in breast cancer tissues by immunohistochemistry. Its higher expression was suggested to correlate positively with the deposition of microcalcifications in the tissues (Bellahcene et al., 1994) . Another study demonstrated a positive relationship between the expression of PTHrP in breast cancer cells and the deposition of microcalcifications in breast cancer tissues, suggesting that the PTHrP secreted by breast cancer cells may alter a local metabolism of calcium and may lead to the deposition of calcified precipitates (Kanbara et al., 1993) .
We recently established a new human breast cancer cell line, designated KPL-3C, which is derived from the malignant effusion of a breast cancer patient with HHM. Preliminary characterisation of this cell line and the inhibitory effect of steroid hormones on PTHrP secretion are described in the present paper.
Materials and methods
The clinical course of the patient A 37-year-old Japanese woman with an invasive ductal carcinoma of the breast underwent a radical mastectomy in October 1990. Local recurrence appeared in July 1991. She received combined treatment including chemoendocrine therapy and radiotherapy to the local recurrent sites between October 1991 and August 1993. Liver metastasis and bilateral pleural effusion were detected at the beginning of September 1993. Then, hypercalcaemia suddenly occurred without any symptoms suggesting bone metastases. Severe hypercalcaemia up to 13.6 mg 100 ml-' (the normal range of our hospital: 8.0-10.0 mg 100 ml-') and a low serum level of inorganic phosphorus down to 1.8 mg 100 ml-' (the normal range: 2.8-5.2 mg 100 ml-') were observed. At the same time, a high blood level of C-terminal PTHrP (287 pmol 11, the normal range: less than 10 pmol 1-1) measured by a radioimmunoassay (SRL Co., Tokyo, Japan) was also detected. 
Chromosomal analysis
Cytogenetic analysis was performed when the cell line had been passed 8 or 35 times. Semi-confluent cells were exposed to 0.1 jIg ml-' colcemid for 4 h and then detached with the trypsin solution. A hypotonic solution of 0.075 M potassium chloride was added, and then the cells were fixed with 3:1 methanol -acetic acid and stained conventionally with Giemsa.
Oestrogen receptor (ER) and progesterone receptor (PgR) analysis ER and PgR in the pellet of the cultured KPL-3C cells or in the tumours transplanted into nude mice were measured by an enzyme immunoassay using the ER-EIA and PgR-EIA kits (Dinabot Inc., Tokyo, Japan) following the manufacturer's recommendations.
Oncogene amplification Total cellular DNA from KPL-3C cells was extracted by a conventional phenol-chloroform method. DNA dot -blot hybridisation was performed as previously described (Kurebayashi et al., 1995) . Briefly, DNA samples were spotted onto Hybond N nylon sheets (Amersham, Arlington Heights, IL, USA) using a Hybri-dot blotting manifold (BRL, Bethesda, MD, USA). Then the sheets were hybridised with 32P-labelled specific DNA probes and exposed to X-ray films. Hybridisation signals were analysed with a BSA2000 bioimaging analyser (Fuji Film, Tokyo, Japan). The degree of amplification was estimated by a comparison with the radioactivity of placental DNA on the same membrane. The actin probe was used as an internal control. The DNA probes were a 1.6 kb EcoRI fragment of human erbB-2, a 3.7 kb SacI fragment of H-ras and a 1.1 kb cDNA of K-ras. All DNA probes were obtained from Otsuka Pharmaceutical (Tokushima, Japan).
Cell growth in vitro and in vivo
Approximately 1 x 105 cells per well were plated in 12-well plates (SB Medical, Tokyo, Japan) and grown in RPMI-1640 medium supplemented with 10% FBS for 2 weeks at 37°C in a 5% carbon dioxide atmosphere. Triplicate wells were trypsinised every other day and the viable cells were counted in a haemocytometer using trypan blue exclusion. The tumour doubling time was estimated from the linear portion of the growth curve. To investigate the tumorigenicity of the KPL-3C cells, semi-confluent KPL-3C cells were trypsinised and harvested. Viable cells were counted in a haemocytometer using trypan blue exclusion and centrifugated, and the cell pellets were resuspended with the medium. Approximately 5 x 106 viable cells per 0.2 ml of the medium were injected into the mammary fat pad (two injections per mouse) of 4-week-old BALB-c-nu/nu female athymic nude mice (Clea Japan, Tokyo, Japan). Tumour volume was calculated as the product of the largest diameter, the orthogonal measurement and the tumour depth. Mean tumour volume was calculated as the sum of the tumour volumes divided by the number of tumours.
Measurement of PTHrP
The PTHrP concentration in the cultured media of KPL-3C cells was measured by a two-site immunoradiometric assay kit (Mitsubishi Petrochemical Co., Tokyo, Japan). A rabbit anti-human PTHrP (50-83) polyclonal antibody and a mouse anti-human PTHrP (1 -34) monoclonal antibody were used in this assay. Recombinant human PTHrP (1-87) was used as the standard. The detection limit of the assay was 0.5 pmol -1, and the coefficients of intra-and interassay variations were not higher than 7.5% for three different concentrations of the PTHrP (1-87) (Ikeda et al., 1994 (Figure 2a) . Interestingly, deposition of microcalcifications was frequently observed in the central necrosis. The deposition was also observed in the ductal structures beside the tumours, which appeared to be lymphatic vessels (Figure 2b ). Each tumour cell had a round or oval-shaped large nucleus with a large nucleolus. Histological examination of the original tumour of the patient revealed a predominant intraductal component associated with a massive central necrosis (Figure 2c ) and some invasive expansion into the stroma. The morphological features of the original tumour of the patient are similar to those of the transplanted KPL-3C tumours.
Ultrastructurally, a large oval or irregular-shaped nucleus with a prominent chromatin and a typical intracytoplasmic lumen was observed in the KPL-3C cells transplanted into nude mice (Figure 3a) . These findings are consistent with cancer cells. In the cytoplasm, many mitochondria and welldeveloped rough endoplasmic reticulum were recognised. In addition, numerous intermediate filaments were observed at the perinuclear region. Occasionally, junctional structures among the tumour cells were seen (Figure 3b Karyotype analysis A total of 50 KPL-3C cells at the 8th or 35th passages were studied, and a detailed analysis by the trypsin method was performed in ten metaphases. The median chromosomal number was 66 with a range from 60 -67 at the 8th passage and 64 with a range from 58-66 at the 35th passage. When G-banding was performed, 18-21 marker chromosomes were found at the 8th passage, and 19-24 at the 35th passage. The common chromosomal aberrations at both passages were lq+, 3p+, 8p+, 12p-, 12p+, 13q+, 14q+, 17p-and l9q+.
Chromosomes number 22 and X were not identified in either passage ( Figure 5 ). These findings suggest that this cell line is derived from a monoclonal human cancer cell and that its karyotype is relatively stable through the serial passages. No gene amplification of c-erbB-2, H-ras and K-ras measured by DNA dot-blot hybridisation was seen in KPL-3C cells. The estimated copy number of the genes was 1.01 for c-erbB-2, 1.51 for H-ras and 1.16 for K-ras.
Cell growth in vitro and in vivo
The population doubling time of the KPL-3C cells was approximately 72 h when the cells grew exponentially in RPMI-1640 medium supplemented with 10% FBS. To investigate tumorigenicity, KPL-3C cells at the 5th, 15th, 29th and 40th passages were injected into the mammary fat pad of female athymic nude mice. The cells from the 5th and 15th passages did not develop tumours at all (0/6 for the 5th passage and 0/12 for the 15th passage). However, the cells from the 29th and 40th passages developed tumours at a take rate of 100% (12/12 for the 29th passage and 10/10 for the 40th passage). The transplanted tumours grew slowly and the tumour doubling time was approximately 1 week. The mean volume of the tumours 6 weeks after the injections was 103 mm3 with a range of Second, since it has been reported that the secretion of PTHrP from the BEN cell line, which is derived from human lung cancer, is drastically stimulated by the addition of a phorbol ester to the culture medium (Deftos et al., 1989) , we studied the effect of PMA on the secretion of PTHrP from KPL-3C cells. Aliquots of 0.01 nM to 100 nm of PMA significantly stimulated the secretion of PTHrP from KPL-3C cells (Figure 6 , P<0.01 in all comparisons between the control and the treated groups). In addition, to examine the inhibitory effect of steroid hormones on PTHrP secretion from KPL-3C cells, three different steroid hormones were added to the culture medium. An aliquot of 0.01 gUM of hydrocortisone significantly increased PTHrP secretion but 1 lM significantly decreased the secretion. In contrast, 0.1 uM-10uM of MPA and 1 nM-100nM of OCT decreased PTHrP secretion in a dose-dependent manner (Figure 6 ).
These findings suggest that PTHrP secretion from KPL-3C cells is stable through serial passages and regulated by the addition of a phorbol ester or steroid hormones to the culture medium.
Microcalcifications in the transplanted tumours
When KPL-3C cells transplanted into nude mice were microscopically observed, there were a number of microcalcifications both inside and beside the tumours as described above. To confirm that they were calcified substances, the resected specimens were radiographed with an X-ray machine. Interestingly, fine, dense and linear or irregularshaped microcalcifications were observed in each tumour (Figure 7 ). These radiographic findings suggest that the microcalcifications of the transplanted tumours are very similar to those commonly observed in human breast cancer. Three transplanted tumours injected with other cell lines (MCF-7, MKL-4 or KPL-1) (Soule et al., 1973; Kurebayashi et al., 1993 Kurebayashi et al., 1995 were also radiographed by the same method. No such microcalcifications were observed in those tumours. (Ellison et al., 1975; Strewler et al., 1983; Sato et al., 1987; Merryman et al., 1989; Miyake et al., 1991; De Miguel and Esbrit, 1992; Ichinose et al., 1993; Tabuenca et al., 1995; Birch et al., 1995) . Although immunohistochemical and molecular analyses clearly demonstrate that the majority of breast cancer cells express PTHrP in primary tumours and metastatic sites and, in particular, in bone metastasis (Southby et al., 1990; Powell et al., 1991; Bundred et al., 1992; Vargus et al., 1992; Bouizar et al., 1993; Kohno et al., 1994a,b) , only a little experimental data have been published so far concerning PTHrP secretion from established breast cancer cell lines (Tabuenca et al., 1995; Birch et al., 1995 (Martin, 1988; Mundy, 1990) . Recently, newly developed agents, such as bisphosphonate, which decrease the osteolytic activity of osteoclasts, have been used clinically for malignancy-associated hypercalcaemia caused by multiple osteolytic metastases or a high blood level of PTHrP secreted by malignancies (Body et al., 1986 (Body et al., , 1989 Dumon et al., 1991) . However, it has been suggested that those agents are less effective against PTHrPinduced hypercalcaemia than against that caused by multiple bone metastases (Body et al., 1993; Walls et al., 1994 
